FLT3 inhibitors such as midostaurin and gilteritinib [55] target FLT3 mutations seen in AML, while JAK2 inhibitors such as ruxolitinib [56] inhibit JAK2, which may be activated in KMT2A‐r leukemia. This evidence concerns the gene JAK2 and acute myeloid leukemia.